Author

Honghui Zhao

Observed name: ZHAO Honghui

Institution: Lanzhou University

Observed institutions: Hebei Medical University, Fourth Hospital of Hebei Medical University, Lanzhou University

ORCID: 0000-0003-0470-5801

Observed ORCID: 0000-0003-0470-5801

OpenAlex ID: A5023643410

Bifidobacterium breve predicts the efficacy of anti‐PD ‐1 immunotherapy combined with chemotherapy in Chinese NSCLC patients

2022 · Honghui Zhao, Dan Li, et al. · Cancer Medicine · 49

ALK fusion typing and response to crizotinib in ALK+ lung cancer-naive patients.

2022 · Xinliang Zhou, Liyuan He, et al. · Journal of Clinical Oncology · 3

The immunological and prognostic landscape of TFAP4 in cancer: A single-cell RNA sequencing perspective

2025 · Linghui Zhong, Zidong Feng, et al. · Archives of Biochemistry and Biophysics · 1

Gut microbiota and association with clinical response to anti-PD-1 based immunotherapy combined with chemotherapy in Chinese patients with lung cancer.

2022 · Honghui Zhao, Liyuan He, et al. · Journal of Clinical Oncology · 1

Single‐Cell and Multiomics Characterization of p21 in Cancer Progression and Therapeutic Sensitivity

2026 · Wenyang Zhang, Qinglong Ma, et al. · Human Mutation

A multidimensional Pan-cancer analysis of CDKN1A identifies CDKN1A as an Immunological and Prognostic Biomarker

2024 · Wenyang Zhang, Qinglong Ma, et al. · bioRxiv (Cold Spring Harbor Laboratory)

Efficacy and prognosis of sequential 2G ALK-TKI in ALK-positive advanced NSCLC after crizotinib resistance: A real-world single-center research.

2022 · Liyuan He, Jing Zuo, et al. · Journal of Clinical Oncology

Works count: 8

Citation count: 54

H-index: 2

I10-index: 1